Novo Nordisk

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s new once-daily pill for weight management, designed…

This article first appeared on GuruFocus. Roche Holding AG (RHHBY) is beginning to show tangible progress in obesity…

Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…

Cash-pay platform brings transparent pricing and direct provider access to first and only oral GLP-1 weight loss medication…

Novo Nordisk had a rough stretch in 2025 that eventually led to it “firing” its CEO. The new…

Novo Nordisk’s Ozempic kicked off the GLP-1 craze when it launched in 2018 for the treatment of Type…

Eli Lilly LLY has emerged as a dominant force in the cardiometabolic market, driven by strong demand for its…

The inside story of the pharmaceutical industry’s efforts to tackle and monetise obesity with Ozempic and other drugs…

Health Canada has approved a GLP-1 pill for the first time. The once-a-day semaglutide pill is approved for…

Wegovy will be heavily subsidised for Australians with severe obesity, who have also experienced a cardiovascular event, like…

jetcityimage / iStock Editorial via Getty Images Lilly posted 53.9% revenue growth and 480% net income growth driven…

This article first appeared on GuruFocus. Amazon Pharmacy (AMZN, Financials) stated that it is now selling Novo Nordisk’s…

US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy